Dolutegravir and Dacarbazine drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Dolutegravir (dolutegravir) and Dacarbazine (dacarbazine). Common drug interactions include febrile bone marrow aplasia among females and lung disorder among males.

The phase IV clinical study analyzes what interactions people have when they take Dolutegravir and Dacarbazine. It is created by eHealthMe based on reports of 18 people who take the same drugs from the FDA, and is updated regularly.

What is Dolutegravir?

Dolutegravir has active ingredients of dolutegravir. eHealthMe is studying from 7,071 Dolutegravir users. Check the latest studies of Dolutegravir.

What is Dacarbazine?

Dacarbazine has active ingredients of dacarbazine. eHealthMe is studying from 8,064 Dacarbazine users. Check the latest studies of Dacarbazine.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 20, 2026

18 people who take Dolutegravir and Dacarbazine together, and have interactions are studied.

Dolutegravir and Dacarbazine drug interactions.

What are the common drug interactions of Dolutegravir and Dacarbazine, by gender? *:

female:

Febrile bone marrow aplasia (bone marrow greatly decreases or stops production of blood cells)
Blood beta-d-glucan increased

male:

Lung disorder (lung disease)
Pulmonary embolism (blockage of the main artery of the lung)
Respiratory failure (inadequate gas exchange by the respiratory system)
Pulmonary toxicity (side effects on the lungs)

What are the common drug interactions of Dolutegravir and Dacarbazine, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

Febrile bone marrow aplasia (bone marrow greatly decreases or stops production of blood cells)
Blood beta-d-glucan increased

40-49:

Lung disorder (lung disease)
Pulmonary embolism (blockage of the main artery of the lung)
Respiratory failure (inadequate gas exchange by the respiratory system)
Pulmonary toxicity (side effects on the lungs)

50-59:

n/a

60+:

n/a

What are the existing conditions these people have? *

Hodgkin's Lymphoma (cancer originating from white blood cells): 17 people, 94.44%
Hiv Infection: 16 people, 88.89%
Transplant Failure (transplantation failed to meet outcome): 2 people, 11.11%
Hodgkin's Disease Lymphocyte Depletion Type Stage Iv (cancer originating from white blood cells stage iv): 1 person, 5.56%
Acquired Immunodeficiency Syndrome (disease of the human immune system caused by the human immunodeficiency virus (hiv)): 1 person, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Dolutegravir and Dacarbazine?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously